Supplementary Figures S1-6 from ErbB3–ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas

Supplementary Figures S1-6 Supplemental Fig. S1. ErbB3 and ErbB4 expression in melanoma cell lines. Supplemental Fig. S2. Depletion of NRG1 inhibits ErbB3 downstream signaling and cell growth in WT/WT melanoma cell lines. Supplemental Fig. S3. Depletion of ErbB3 reduces AKT and ERK1/2 phosphorylation. Supplemental Fig. S4. huHER3-8 reduces AKT phosphorylation. Supplemental Fig. S5. Pertuzumab reduces phosphorylation of AKT and ERK1/2 and inhibits cell growth. Supplemental Fig. S6. MEK inhibitors increase pertuzumab efficacy in xenografts.